Cytokeratin-positive Malignant Tumor in the Abdomen With EWSR1/FUS-CREB Fusion: A Clinicopathologic Study of 8 Cases.


Journal

The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904

Informations de publication

Date de publication:
01 01 2022
Historique:
pubmed: 29 5 2021
medline: 15 2 2022
entrez: 28 5 2021
Statut: ppublish

Résumé

ATF1, CREB1, and CREM, which encode the CREB family of transcription factors, are fused with EWSR1 or FUS in human neoplasms, such as angiomatoid fibrous histiocytoma. EWSR1/FUS-CREB fusions have recently been reported in a group of malignant epithelioid tumors with a predilection to the peritoneal cavity and frequent cytokeratin expression. Here, we studied 8 cytokeratin-positive abdominal malignancies with these fusions for further characterization. The tumors affected males (15 to 76 y old) and presented as intra-abdominal masses with concurrent or subsequent peritoneal dissemination, ascites, and/or metastases to the liver or lymph nodes. Four patients died of the disease within 18 to 140 months. Cases 1 to 5 showed multinodular growth of monomorphic epithelioid cells with focal serous cysts. Lymphoplasmacytic infiltration was prominent and was associated with systemic inflammatory symptoms. Two patients suffered from membranous nephropathy with nephrosis. The tumors displayed partly overlapping phenotypes with malignant mesothelioma, including diffuse strong expression of AE1/AE3 and WT1 and membranous positivity of sialylated HEG1, although calretinin was negative. Case 6 showed similar histology to cases 1 to 5, but expressed smooth muscle actin diffusely, lacked WT1 and HEG1, and harbored prominent pseudoangiomatous spaces. Cases 7 and 8 displayed dense growth of small oval to short spindle cells, with occasional molding and minor swirling, superficially resembling small cell carcinoma. Lymphoplasmacytic infiltration was not observed. The tumors were positive for AE1/AE3 and CD34 (focal), whereas calretinin, WT1, and HEG1 were negative. The detected fusions were FUS-CREM (n=4), EWSR1-ATF1 (n=2), EWSR1-CREB1 (n=1), and EWSR1-CREM (n=1). We confirmed the prior observation that these tumors do not fit perfectly with known entities and provided additional novel clinicopathologic information. The tumors require wider recognition because of more aggressive behavior than angiomatoid fibrous histiocytoma despite similar genetics, and potential misdiagnosis as unrelated diseases, such as neuroendocrine neoplasms.

Identifiants

pubmed: 34049318
doi: 10.1097/PAS.0000000000001742
pii: 00000478-202201000-00022
doi:

Substances chimiques

Biomarkers, Tumor 0
CREM protein, human 0
EWSR1-ATF1 fusion protein, human 0
EWSR1-CREB1 fusion protein, human 0
FUS protein, human 0
Oncogene Proteins, Fusion 0
RNA-Binding Protein FUS 0
Cyclic AMP Response Element Modulator 135844-64-3
Keratins 68238-35-7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

134-146

Informations de copyright

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest and Source of Funding: Supported in part by JSPS Grant-in-Aid for Young Scientists 18K15108 (A.Y.). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.

Références

Lonze BE, Ginty DD. Function and regulation of CREB family transcription factors in the nervous system. Neuron. 2002;35:605–623.
Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol. 2001;2:599–609.
Rauen T, Hedrich CM, Tenbrock K, et al. cAMP responsive element modulator: a critical regulator of cytokine production. Trends Mol Med. 2013;19:262–269.
Zucman J, Delattre O, Desmaze C, et al. EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet. 1993;4:341–345.
Antonescu CR, Nafa K, Segal NH, et al. EWS-CREB1: a recurrent variant fusion in clear cell sarcoma—association with gastrointestinal location and absence of melanocytic differentiation. Clin Cancer Res. 2006;12:5356–5362.
Rossi S, Szuhai K, Ijszenga M, et al. EWSR1-CREB1 and EWSR1-ATF1 fusion genes in angiomatoid fibrous histiocytoma. Clin Cancer Res. 2007;13:7322–7328.
Antonescu CR, Dal Cin P, Nafa K, et al. EWSR1-CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma. Genes Chromosomes Cancer. 2007;46:1051–1060.
Antonescu CR, Katabi N, Zhang L, et al. EWSR1-ATF1 fusion is a novel and consistent finding in hyalinizing clear-cell carcinoma of salivary gland. Genes Chromosomes Cancer. 2011;50:559–570.
Flucke U, Mentzel T, Verdijk MA, et al. EWSR1-ATF1 chimeric transcript in a myoepithelial tumor of soft tissue: a case report. Hum Pathol. 2012;43:764–768.
Kao YC, Sung YS, Zhang L, et al. EWSR1 fusions with CREB family transcription factors define a novel myxoid mesenchymal tumor with predilection for intracranial location. Am J Surg Pathol. 2017;41:482–490.
Thway K, Nicholson AG, Lawson K, et al. Primary pulmonary myxoid sarcoma with EWSR1-CREB1 fusion: a new tumor entity. Am J Surg Pathol. 2011;35:1722–1732.
Desmeules P, Joubert P, Zhang L, et al. A subset of malignant mesotheliomas in young adults are associated with recurrent EWSR1/FUS-ATF1 fusions. Am J Surg Pathol. 2017;41:980–988.
Thway K, Fisher C. Angiomatoid fibrous histiocytoma: the current status of pathology and genetics. Arch Pathol Lab Med. 2015;139:674–682.
Argani P, Harvey I, Nielsen GP, et al. EWSR1/FUS-CREB fusions define a distinctive malignant epithelioid neoplasm with predilection for mesothelial-lined cavities. Mod Pathol. 2020;33:2233–2243.
Yoshida A, Wakai S, Ryo E, et al. Expanding the phenotypic spectrum of mesenchymal tumors harboring the EWSR1-CREM Fusion. Am J Surg Pathol. 2019;43:1622–1630.
Tsuji S, Washimi K, Kageyama T, et al. HEG1 is a novel mucin-like membrane protein that serves as a diagnostic and therapeutic target for malignant mesothelioma. Sci Rep. 2017;7:45768.
Sunami K, Ichikawa H, Kubo T, et al. Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: a hospital-based study. Cancer Sci. 2019;110:1480–1490.
Hung YP, Dong F, Torre M, et al. Molecular characterization of diffuse malignant peritoneal mesothelioma. Mod Pathol. 2020;33:2269–2279.
Saito K, Kobayashi E, Yoshida A, et al. Angiomatoid fibrous histiocytoma: a series of seven cases including genetically confirmed aggressive cases and a literature review. BMC Musculoskelet Disord. 2017;18:31.
Chen G, Folpe AL, Colby TV, et al. Angiomatoid fibrous histiocytoma: unusual sites and unusual morphology. Mod Pathol. 2011;24:1560–1570.
Waters BL, Panagopoulos I, Allen EF. Genetic characterization of angiomatoid fibrous histiocytoma identifies fusion of the FUS and ATF-1 genes induced by a chromosomal translocation involving bands 12q13 and 16p11. Cancer Genet Cytogenet. 2000;121:109–116.
Cheah AL, Zou Y, Lanigan C, et al. ALK expression in angiomatoid fibrous histiocytoma: a potential diagnostic pitfall. Am J Surg Pathol. 2019;43:93–101.
Fanburg-Smith JC, Miettinen M. Angiomatoid “malignant” fibrous histiocytoma: a clinicopathologic study of 158 cases and further exploration of the myoid phenotype. Hum Pathol. 1999;30:1336–1343.
Thway K, Nicholson AG, Wallace WA, et al. Endobronchial pulmonary angiomatoid fibrous histiocytoma: two cases with EWSR1-CREB1 and EWSR1-ATF1 fusions. Am J Surg Pathol. 2012;36:883–888.
Hasegawa T, Seki K, Ono K, et al. Angiomatoid (malignant) fibrous histiocytoma: a peculiar low-grade tumor showing immunophenotypic heterogeneity and ultrastructural variations. Pathol Int. 2000;50:731–738.
Morgan MB, Pitha J, Johnson S, et al. Angiomatoid malignant fibrous histiocytoma revisited. An immunohistochemical and DNA ploidy analysis. Am J Dermatopathol. 1997;19:223–227.
Naso JR, Tsuji S, Churg A. HEG1 is a highly specific and sensitive marker of epithelioid malignant mesothelioma. Am J Surg Pathol. 2020;44:1143–1148.
Akiyama M, Yamaoka M, Mikami-Terao Y, et al. Paraneoplastic syndrome of angiomatoid fibrous histiocytoma may be caused by EWSR1-CREB1 fusion-induced excessive interleukin-6 production. J Pediatr Hematol Oncol. 2015;37:554–559.
Potter SL, Quintanilla NM, Johnston DK, et al. Therapeutic response of metastatic angiomatoid fibrous histiocytoma carrying EWSR1-CREB1 fusion to the interleukin-6 receptor antibody tocilizumab. Pediatr Blood Cancer. 2018;65:e27291.
Villiger PM, Cottier S, Jonczy M, et al. A simple Baker’s cyst? Tocilizumab remits paraneoplastic signs and controls growth of IL-6-producing angiomatoid malignant fibrous histiocytoma. Rheumatology (Oxford). 2014;53:1350–1352.
Galesic K, Bozic B, Heinzl R, et al. Pleural mesothelioma and membranous nephropathy. Nephron. 2000;84:71–74.
Kohorst MA, Tran CL, Folpe AL, et al. Membranous nephropathy associated with angiomatoid fibrous histiocytoma in a pediatric patient. Pediatr Nephrol. 2014;29:2221–2224.
Arbajian E, Puls F, Antonescu CR, et al. In-depth genetic analysis of sclerosing epithelioid fibrosarcoma reveals recurrent genomic alterations and potential treatment targets. Clin Cancer Res. 2017;23:7426–7434.
Memon RA, Granada CNP, Patel C, et al. Gastric sclerosing epithelioid fibrosarcoma harboring a rare FUS-CREM fusion. Int J Surg Pathol. 2020:1066896920961174. [Epub ahead of print].
Sloan EA, Chiang J, Villanueva-Meyer JE, et al. Intracranial mesenchymal tumor with FET-CREB fusion-A unifying diagnosis for the spectrum of intracranial myxoid mesenchymal tumors and angiomatoid fibrous histiocytoma-like neoplasms. Brain Pathol. 2020:e12918. [Epub ahead of print].

Auteurs

Takahiro Shibayama (T)

Departments of Diagnostic Pathology.

Tatsunori Shimoi (T)

Medical Oncology.
Rare Cancer Center, National Cancer Center Hospital, Tokyo, Japan.

Taisuke Mori (T)

Departments of Diagnostic Pathology.

Emi Noguchi (E)

Medical Oncology.

Yoshitaka Honma (Y)

Head and Neck Medical Oncology Division.
Rare Cancer Center, National Cancer Center Hospital, Tokyo, Japan.

Susumu Hijioka (S)

Hepatic and Pancreatobiliary Oncology.
Rare Cancer Center, National Cancer Center Hospital, Tokyo, Japan.

Masayuki Yoshida (M)

Departments of Diagnostic Pathology.

Chitose Ogawa (C)

Pediatric Oncology.
Rare Cancer Center, National Cancer Center Hospital, Tokyo, Japan.

Kan Yonemori (K)

Medical Oncology.
Rare Cancer Center, National Cancer Center Hospital, Tokyo, Japan.

Yasushi Yatabe (Y)

Departments of Diagnostic Pathology.

Akihiko Yoshida (A)

Departments of Diagnostic Pathology.
Rare Cancer Center, National Cancer Center Hospital, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH